Financiere des Professionnels Fonds d investissement inc. Purchases 12,264 Shares of Becton, Dickinson and Company $BDX

Financiere des Professionnels Fonds d investissement inc. boosted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 10.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 125,024 shares of the medical instruments supplier’s stock after purchasing an additional 12,264 shares during the quarter. Becton, Dickinson and Company comprises 1.4% of Financiere des Professionnels Fonds d investissement inc.’s holdings, making the stock its 13th biggest position. Financiere des Professionnels Fonds d investissement inc.’s holdings in Becton, Dickinson and Company were worth $24,263,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its position in shares of Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 877 shares during the period. Assetmark Inc. grew its position in shares of Becton, Dickinson and Company by 49.5% in the 3rd quarter. Assetmark Inc. now owns 225,967 shares of the medical instruments supplier’s stock valued at $42,294,000 after purchasing an additional 74,795 shares during the period. Vanguard Group Inc. grew its position in shares of Becton, Dickinson and Company by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 32,455,790 shares of the medical instruments supplier’s stock valued at $6,074,750,000 after purchasing an additional 147,041 shares during the period. Skba Capital Management LLC grew its position in shares of Becton, Dickinson and Company by 1,619.9% in the 3rd quarter. Skba Capital Management LLC now owns 57,514 shares of the medical instruments supplier’s stock valued at $10,765,000 after purchasing an additional 54,170 shares during the period. Finally, Graybill Wealth Management LTD. grew its position in shares of Becton, Dickinson and Company by 47.3% in the 3rd quarter. Graybill Wealth Management LTD. now owns 27,592 shares of the medical instruments supplier’s stock valued at $5,164,000 after purchasing an additional 8,859 shares during the period. 86.97% of the stock is owned by institutional investors.

Becton, Dickinson and Company Stock Down 2.6%

BDX opened at $148.14 on Thursday. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $187.35. The stock’s fifty day simple moving average is $150.40 and its 200 day simple moving average is $174.56. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The stock has a market cap of $40.82 billion, a PE ratio of 37.50, a price-to-earnings-growth ratio of 10.76 and a beta of 0.22.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The business had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.67 billion. During the same quarter in the prior year, the business earned $3.35 EPS. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, research analysts expect that Becton, Dickinson and Company will post 12.61 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be paid a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date is Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio is 106.33%.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on BDX shares. Barclays boosted their price objective on Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Piper Sandler reduced their price target on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating for the company in a research report on Friday, April 17th. TD Cowen reduced their price target on Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating for the company in a research report on Monday, May 4th. Stifel Nicolaus reduced their price target on Becton, Dickinson and Company from $215.00 to $175.00 in a research report on Thursday, May 7th. Finally, Royal Bank Of Canada set a $175.00 price target on Becton, Dickinson and Company in a research report on Tuesday, April 14th. Seven analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $183.64.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the transaction, the chief executive officer owned 110,163 shares in the company, valued at $16,122,355.05. This trade represents a 2.45% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 2,913 shares of company stock worth $426,806. 0.40% of the stock is owned by company insiders.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.